Kidney transplantation is the best form of renal replacement therapy (RRT) for end-stage renal disease (ESRD) patients. In India, only 10% of ESRD patients receive any form of RRT and only 2% undergo renal transplantation. [1] As per the Indian chronic kidney disease (CKD) registry, 39% of CKD Stage 5 patients were on RRT, of which only 2% were being worked up for renal transplantation. [2] Deceased donor transplantation is still in its nascent stage, and despite ongoing efforts, it constitutes a small fraction of total transplants performed in our country. There is a significant demand and supply mismatch for living donor renal transplantation. To compound the problem, ABO incompatibility leads to rejection of almost 35% of the otherwise suitable donors. [3] The published experience of ABO-incompatible (ABOi) renal transplant from India has been far and few. We hereby present our experience of initial fifty ABOi renal transplants.
physical examination. After completing the workup, complement-dependent cytotoxicity (CDC) and flow cytometry crossmatch were done before proceeding for preconditioning protocol.
Preconditioning
Preconditioning protocol consisted of intravenous (IV) rituximab (200 mg) administration 2 weeks pretransplant. A week after this, tacrolimus (0.05 mg/kg/day in two divided doses) and mycophenolate sodium (720 mg twice daily) were started, and the patient was admitted for isoagglutinin removal by cascade plasmapheresis. Target tacrolimus trough level was 8-12 ng/ml. On alternate day, cascade plasmapheresis (CP) was performed followed by administration of IV immunoglobulin (IVIG) (100 mg/kg/dose). Isoagglutinin IgG titer was monitored on daily basis and transplantation was done once the titer reached ≤8. Intraoperatively, IV methylprednisolone (500 mg) and basiliximab (20 mg) were given as induction. Another dose of basiliximab was repeated on the 4 th postoperative day. IV hydrocortisone was given on the day of transplant followed by oral prednisolone at 40 mg/day next day onward. This was tapered to 20 mg/day on discharge. Daily monitoring of isoagglutinin titer was done till discharge and CP sessions were given in case of persistently rising titers.
Follow-up
Patient follow-up was done twice weekly for the 1 st month, weekly for the next 1 month, once in a fortnight till the 3 rd month, and monthly thereafter for 1 year. After 1 st year, follow-up was done once in 2-3 months. During every visit, renal function tests including serum creatinine and hemogram were monitored. Isoagglutinin titer was monitored twice weekly for 2 weeks postdischarge. Tacrolimus trough level target was 8-12 ng/ml during first 3 months, 5-8 ng/ml from 3 to 6 months, and <5 ng/ml thereafter. Prednisolone was tapered to 10 mg by the end of 3 months and 5 mg by the end of 6 months. Mycophenolate sodium was tapered to 360 mg twice daily by 6 months.
Protocol graft biopsy at 3 months' posttransplant was done for initial nine ABOi renal transplant recipients. Later, it was discontinued due to unwillingness of the patients. Graft biopsies were also performed whenever indicated such as in case of rising serum creatinine. All the graft biopsies were examined by light microscopy and immunofluorescence including C4d. All rejections were biopsy proven.
Statistical analysis was done using MedCalc for Windows, version 12.7.8 (MedCalc Software, Belgium). Data were reported as mean ± standard deviation values.
rEsults
As discussed, fifty patients who completed at least 6 months of follow-up were included for the final analysis. Median follow-up was 31 months (range, 8-38 months). Table 1 shows baseline characteristics of the patients. Figure 1 shows blood group distribution of transplanted recipients and donors. Majority of the patients were O blood group recipients. Figure 2 shows antibody titers of the recipients. Median antibody titer was 256. Table 2 shows the patient outcome. Biopsy-proven acute rejection (BPAR) was 22% (n = 11). Four patients had acute antibody-mediated rejection within 24 h of transplant. None of these four grafts could be salvaged despite prompt plasma exchange. All of these acute antibody-mediated rejections showed prominent finding of thrombotic microangiopathy. There was no correlation between antibody titer and rejection. Table 3 shows the cause of patient and graft loss. Infection was an important cause of patient loss. Figure 3 shows the Kaplan-Meier curves for patient and graft survival and acute rejection-free survival.
disCussion
Conventionally, ABO incompatibility has been considered as an important immunological barrier and an absolute contraindication for renal transplantation. [4] [5] [6] Initial attempts to do ABOi renal transplants in the 1950s and 60s were met with high failure. It was not until the 1980s when the successful use of plasma exchange and splenectomy lead to significant improvement in graft outcomes of ABOi renal transplant recipients. [7] With further improvements in preconditioning protocols over the last few decades, it became possible to do ABOi renal transplants with graft and patient survival at par with ABO-compatible transplants. [8] [9] [10] Patient survival was 94% in the current study. This was 98% in the study by Tyden et al. and 100% in the study by Flint et al. and Lipshutz et al. [11] [12] [13] In the UK national registry data of ABOi renal transplant recipients, the patient survival rate at 5 years was 91%. [14] Death-censored graft survival of ABOi transplant group in our study was 88%. This is similar to the good graft survival in the study by [11, 12, 14] BPAR rate in ABOi recipients in the current study was 22%. This was better than the BPAR of 40% in a study by Wilpert et al. [15] Lipshutz et al. and Uchida et al. reported BPAR of 11% and 32%, respectively. [13, 16] Most of the studies have reported 5%-33% incidence of antibody-mediated rejection (AMR) in ABOi recipients. In our study, 4 (8%) ABOi recipients developed AMR, leading to graft loss in all of them.
Graft biopsies showed C4d staining in 64% of the cases. In various studies, C4d positivity in protocol graft biopsies has been seen in 80%-94% of patients and does not necessarily indicate AMR. [17, 18] In biopsies showing finding other than AMR, C4d was positive in 56% of the cases. The presence of C4d positivity in the presence of normal graft function and antiblood group antibodies in blood represents the phenomenon of accommodation.
Infection rate was 22% in the present study. Infection was an important cause of mortality. Infection has been reported as the most common cause of death in previous studies as well. [19, 20] This appears to be because of higher immunosuppression burden due to preconditioning and efforts are ongoing to minimize immunosuppression by decreasing desensitization intensity and maintenance immunosuppression dosage in these patients.
There are few limitations of the present study. This is a retrospective study. The follow-up of patients is relatively short. The sample size is small. Despite these limitations, this is one of the largest single-center experience of ABOi renal transplant from India. There are few unanswered questions in the field of ABOi transplant. There is a lack of controlled trials and which preconditioning protocol is the best is largely unknown. What dose of rituximab should be used? Should we use it at all as there are studies showing that ABOi transplants can be done even in its absence? What is the role and necessity of empirically administered postpheresis IVIG? What is the optimal immediate pretransplant antibody titer? What are the factors causing AMR in an ABOi transplant recipient? These are just a few out of the many unanswered questions in this ever-evolving field. As noted in Table 2 , so far, 4 of our ABOi patients had AMR leading to graft loss. The antibody titer remained in acceptable range despite the rejection. Pretransplant CDC and flow cytometry crossmatch in all these patients was negative. Single-antigen bead assay to detect antihuman leukocyte antigen-antibody was done in three of these patients, but no donor-specific antibody could be detected.
ConClusion
There are few published series of ABOi renal transplant from developing countries. Ours is the first series of fifty ABOi renal transplants. Although the rate of AMR was higher than those for ABO-compatible grafts, the graft and patient survival were good in the present study. BPAR was at par with others worldwide, and the rate of infection was also comparable with other studies. ABOi transplant rates should be encouraged to increase the scarce living donor pool.
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rEfErEnCEs Figure 3 : Kaplan-Meier graphs for patient survival, graft survival, and acute rejection-free survival
